Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M118 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| M118 | DRUG | intravenous (IV) infusion |
| Unfractionated Heparin | DRUG | IV infusion |
M118 is an investigational small molecule being developed for Coronary Artery Disease (CAD). It is intended for use in patients undergoing percutaneous coronary intervention, a procedure to open blocked coronary arteries. The drug is currently in Phase 2 clinical development and is not yet approved for any use.
M118 is a small molecule developed for Coronary Artery Disease. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its effects in patients undergoing percutaneous coronary intervention, but its mechanism of action is not publicly detailed.
M118 is being developed by Johnson & Johnson, a company listed on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research on this investigational drug for the treatment of Coronary Artery Disease.
M118 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 2 trial for M118 has been completed, and the drug is not currently in any active clinical trials.
M118 has been studied in one completed Phase 2 clinical trial, identified as NCT00543400, titled "Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)." This trial enrolled 503 participants with Coronary Artery Disease. There are no active trials for M118 at this time.
M118 is the drug being investigated in the EMINENCE trial, which is the clinical study titled "Evaluation of M118 in Percutaneous Coronary Intervention." EMINENCE is the name of the trial, not an alternative name for the drug itself. The drug is referred to as M118 in clinical research.